Study of Effect of High-Flux Versus Low-Flux Dialysis Membranes on Parathyroid Hormone

Ahmed Rabie El Arbagy¹, Mahmoud Abd El Aziz Koura¹, Abd El Samad Sobhy Abou El Nasr² and Hany Said Elbarbary^1,

¹Departments of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt

²Internal Medicine Department, Benha teaching hospital, Qalyobia, Egypt

Cite this paper:
Ahmed Rabie El Arbagy, Mahmoud Abd El Aziz Koura, Abd El Samad Sobhy Abou El Nasr and Hany Said Elbarbary. Study of Effect of High-Flux Versus Low-Flux Dialysis Membranes on Parathyroid Hormone. American Journal of Clinical Medicine Research. 2014; 2(1):36-42. doi: 10.12691/ajcmr-2-1-9

Abstract

Objective: Investigate the influence of permeability of low-flux versus high-flux dialysis membranes on intact PTH during hemodialysis. Background: Hyperparathyroidism is a common finding in patients with renal insufficiency and parathyroid hormone (PTH) is considered a uremic toxin responsible for many of the abnormalities of the uremic state and bone disease. Materials and Methods: Forty adult patients on regular hemodialysis were enrolled in a prospective study. Low-flux polysulfone membranes were used for at least 6 months and then the patients were switched to use high-flux polysulfone membranes for 1 month. Serum electrolytes and intact PTH before and after dialysis were compared before and after changes in dialysis membrane. Results: At the end of the 1-month use of high-flux filters, predialysis intact PTH level (415.96 ± 226.72 ng/dL) showed a significant decline (P < 0.05) compared to the predialysis intact PTH (312.28 ± 191.98 ng/dL) with low-flux membranes. Intact PTH level correlated negatively with serum calcium and positively with serum phosphorus levels only in the predialysis samples with the use of low-flux but not high-flux filters. Conclusion: High-flux dialysis membranes are more efficient in removal of intact PTH, one of the middle-sized uremic toxins, than low-flux membranes.

Keywords:
Parathyroid hormone ESRD hemodialysis membrane

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Valder rabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001; 38: 443-64.
[2]	Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355-66.
[3]	Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant. 2004; 19: 293-6.
[4]	Vanholder RC, Glorieux GL, De Smet RV. Back to the future: middle molecules, high flux membranes, and optimal dialysis. Hemodial Int. 2003; 7: 52-7.
[5]	Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008; 19: 863-70.
[6]	De Francisco AL, Cobo MA, Setien MA, et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int. 1998; 54: 2140-5.
[7]	De Francisco AL, Amado JA, Prieto M, et al. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism. Nephron.1994; 66: 442-6.
[8]	Morton AR, Hercz G, Coburn JW. Control of hyperphosphatemia in chronic renal failure. Semin Dial.1990; 3: 219-23.
[9]	Farrell CE. (1984): Electrolytes. In clinical chemistry theory. Analysis and correlation. The C.V. Mosby Company. Kaplan L.A., Pesce. A.J (Ed), 55, P 1054.
[10]	Fraser, Jones G, Kook SH, et al. (1987): Calcium and phosphate metabolism. In: NWTietz, (ed), Fundanintal of clinical chemistry. WB Saunders Company, Philadelphia, 3rd Edition, P 705-728.
[11]	Burtis CA and Ashwood ER. (1986): Tietz Text book of clinical chemistry, W.B. Saunders, 589.
[12]	Balducci A, Coen G, Manni M, et al. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis, Artif Organs.2004; 28 (12): 1067-75.
[13]	Makar SH, Sawiries HK, Farid TM, et al. (2010): Effect of high flux versus low flux dialysis membranes on parathyroid hormone. IJKD 4: 327-32.
[14]	Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63: 1934-43.
[15]	Krieter DH, Canaud B. High permeability of dialysis membranes: what is the limit of albumin loss? Nephrol Dial Transplant. 2003; 18: 651-4.
[16]	Lindsay RM, Spanner E. A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis. 1989; 13: 382-9.
[17]	Marcus RG, Cohl E, Uribarri J. Middle molecule clearance does not influence protein intake in hemodialysis patients. Am J Kidney Dis. 1998; 31: 491-4.
[18]	Bergstrom J. Mechanisms of uremic suppression of appetite. J Ren Nutr. 1999; 9: 129-32.
[19]	Ayli M, Ayli D, Azak E, et al (2005): the effects of high-Flux Hemodialysis on dialysis-Associated Amyloidosis, Renal Failure; 27 (1): 31-34.
[20]	Li Y, Wang Y, Lv J, et al. (2013): Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer. Ren Fail. 2013 Oct; 35 (9): 1240-5.
[21]	Velasquez MT, Albertini B, Lew SQ, et al. (1998): Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis, American Journal of Kidney Diseases; 31 (4): 618-623.
[22]	Takenaka T, Kobayashi K and Suzuki H. (2001): Warning of high-flux hemodialysis, Ren Fail; 23 (6): 819-25.
[23]	Locatelli F, Andrull S, Pecchini F, et al. (2000): Effect of high flux dialysis on the anaemia of haemodialysis patients, Nephrol, Dial, Transplant, 15, 1399-1409.
[24]	Schneider A, Drechsler C, Krane V, et al. (2012): The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: Results of the MINOXIS Study, Clinical Journal of the American Society of Nephrology, Avilable at: http://www.mdlinx.com/ nephrology/news, last update on Januwary17, 2012. Accessed on Febrowary 12, 2012.
[25]	Locatelli F, Vecchio LD, Andrulli S, et al. (2001): Dialysis: its role in optimizing recombinant erythropoietin treatment. Nephrol Dial Transplant 16 (Supp 7): 29-35.
[26]	Drueke TB and Eckardt K. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant.2002; 17 (Supp 5): 28-31.
[27]	Urena P, Eckardt KU, Sarfati E, et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron.1991; 59; 384-393.
[28]	Foulks CJ, Mills GM and Wright LF. Parathyroid hormoe and anaemia-an erythrocyte osmotic fragility study in primary and secondary hyperparathyroidism. Postgrad Med J.1989; 65: 136-139.